Doctors warned of NeutroSpec use on patients with cardiopulmonary problems
This article was originally published in Clinica
Executive Summary
Two patients have died of cardiopulmonary failure within half an hour of receiving an injection of NeutroSpec, a radiopharmaceutical imaging agent developed by Palatin Technologies for the diagnosis of equivocal appendicitis. The deaths, as well as other reports of severe reactions following administration of the agent, have led the Cranbury, New Jersey firm and its NeutroSpec marketing partner Mallinkrodt Imaging to alert doctors on the use of NeutroSpec in patients with underlying cardiopulmonary problems.